Novocure bags mesothelioma nod for electric fields cancer therapy with some limitations
Novocure has secured the FDA’s blessing for another use of its tumor treating fields: malignant pleural mesothelioma, a rare cancer that develops in the linings of the lung and chest.
The NovoTTF-100L System is to be deployed with Eli Lilly’s Alimta (pemetrexed) and a platinum-based chemotherapy in the first-line treatment of unresectable, locally advanced or metastatic forms of the disease. Currently, only 10% to 20% of MPM patients are candidates for surgery to remove the tumor, according to Mary Hesdorffer of the Mesothelioma Applied Research Foundation.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.